Even though PPARα ligands could be used to combat hepatic steatosis in non-alcoholic fatty liver disease (NAFLD), it is evident that PPARα ligands reduce liver fat in rodents19, 20, but not necessarily in humans21. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.